# ATALANTE-1 (NCT02654587)

> OSE2101 Versus Chemotherapy in HLA-A2 Positive Patients With Advanced NSCLC After Immune Checkpoint Inhibitor Failure

No report yet. It can be ordered.

- Drugs tested: OSE2101
- Indication: HLA-A2-positive advanced NSCLC after immune checkpoint inhibitor failure

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02654587
- Phase: PHASE3
- Status: TERMINATED
- Sponsor: OSE Immunotherapeutics
- Conditions: Non Small Cell Lung Cancer
- Interventions: OSE2101; Docetaxel; Pemetrexed
- Enrollment: 219
- Primary outcome: Overall Survival (OS)

## Indexed commentary on ATALANTE-1 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 11
- YouTube: 3
- Podcasts: 1

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=atalante-1-nct02654587

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT02654587", "email": "<work email>"}; the inbox owner confirms by the emailed link.